Novartis enlists Molecular Partners on radioligand therapy discovery; Galera blames CRO error for PhIII failure — claims success after all
A setback in Covid-19 didn’t stop Novartis from teaming up with Molecular Partners again. And this time, they will be looking for radiopharmaceuticals.
Having bet big on the field, Novartis now wants to test a different way of building these therapies — by conjugating radioligands with Molecular Partners’ antibody mimetics.
DARPin, as the class of proteins is known, are genetically engineered proteins that can target specific antigens just like traditional antibodies but are much smaller. When applied to radioligand therapies, it promises to deliver cancer-killing radiation precisely to tumor cells (while sparing healthy ones).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.